BenevolentAI | SPAC Presentation Deck | 42 slides

BenevolentAI · 2021-12
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON

Slide inventory

42
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
Standard legal disclosure slide for a pitch deck.other
04
Standard legal disclosure slide for a SPAC or M&A transaction.other
05
The slide uses a split-layout: left side for team bios with headshots and logos, right side for numbered value propositions.other
06
The slide uses a numbered list format to present key strategic arguments.argue_timing
07
inspire_vision
08
The slide uses a structured layout to contrast industry metrics with the underlying scientific challenges.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
09
The slide combines company background, team metrics, pipeline highlights, and a numbered list of platform value drivers.establish_context
Open slide detailBeat · AgitateLoop · Cost Of Inaction
10
The slide is divided into two sections: Leadership (left) and Selected Board Members & Strategic Advisors (right).other
11
Minimalist design with a stylized golden curve graphic.transition
12
The slide uses a process diagram to show the workflow and a callout box to list benefits.present_solution
Open slide detailBeat · Solution
13
The slide uses a hub-and-spoke diagram to represent the knowledge graph, flanked by data metrics and a summary callout box.present_solution
14
The slide uses a process flow diagram to explain how AI integrates public/proprietary data into a knowledge graph, which is then validated and used for drug dispresent_solution
15
The slide uses a circular diagram to represent a continuous feedback loop between lab capabilities and data integration.present_solution
16
The slide uses a process flow diagram to illustrate the transition from raw data to target prediction and biomarker identification.present_solution
17
The slide uses a process flow diagram to map specific technical capabilities to stages of drug discovery.present_solution
18
The slide uses a mix of bullet points for strategy and a sidebar for quantitative IP metrics.other
19
The slide uses a combination of a table for key metrics and a bar chart to visualize the cumulative impact of PoS improvements across clinical phases.present_solution
20
transition
21
The chart uses a Gantt-like visualization to show pipeline maturity. Includes a callout box for key highlights and market opportunity metrics.show_traction
Open slide detailLoop · Quick Win Big Bet
22
The slide uses a split-layout: left side defines the disease burden and market size, right side defines the mechanism of action for the drug candidate.frame_problem
Open slide detailLoop · Quick Win Big Bet
23
Includes technical data on IC50, cytokine inhibition (TNFa, IL-4), and CGRP inhibition in DRG neurons.present_solution
Open slide detailLoop · Quick Win Big Bet
24
The slide outlines a two-part clinical trial process with a mid-trial review phase.plan_implementation
Open slide detailLoop · Quick Win Big Bet
25
Includes a breakdown of disease severity percentages and a specific drug candidate profile.frame_problem
26
Includes a biological pathway diagram, a scatter plot showing differential RNA expression, and two bar charts showing cytokine reduction.present_solution
27
The slide uses a timeline visualization combined with three descriptive pillars representing key development stages.show_traction
28
transition
29
Highlights a specific high-impact success story involving Eli Lilly.show_traction
30
Includes a call-to-action button for a collaboration video.illustrate_case
31
transition
32
The slide uses a process flow diagram to illustrate how the platform generates assets and the decision criteria for commercialization.present_solution
33
The slide uses a split-view (A/B) to contrast internal development vs out-licensing. The table provides specific illustrative financial milestones for out-licenpresent_solution
34
The chart illustrates a non-risk-adjusted pipeline progression.show_traction
35
The slide uses a hub-and-spoke diagram to link the company to its five strategic priorities for capital deployment.plan_implementation
36
analyze_data
37
Includes detailed footnotes regarding lock-up provisions and transaction assumptions.analyze_data
38
plan_implementation
39
The slide uses a competitive matrix to justify the company's valuation relative to peers.compare_peers
40
summarize
41
transition